The findings that high levels of ULK1 are associated with poor prognosis in several solid tumors [28, 37] and that ULK1 inhibition can rescue the phenotype induced by caspase-3 deletion in AML1/ETO AML cells [38] suggest that ULK1 is a promising new therapeutic target for cancers. This evidence concerns the gene RUNX1 and acute myeloid leukemia.